FDA approves Eli Lilly’s Mounjaro for weight loss
- Update Date:
- Post Date:
The Food and Drug Administration has approved Eli Lilly and Company’s (LLY) Mounjaro, under the name Zepbound, for the treatment of obesity. Previously, Novo Nordisk’s (NVO) Wegovy and Ozempic were the only pharmaceutical options approved for obesity and weight management in the GLP-1 category. Yahoo Finance’s health reporter Anjalee Khemlani breaks down all the details, providing insights on what this could mean for the future of obesity drugs. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international […]